News brief.
An unintended consequence of state regulators getting tougher about enforcing health insurance solvency standards is putting Illinois in a squeeze. Three insurers have been forced into liquidation by the state Department of Insurance over the past year, and their members have come knocking on the door of a state program set up 11 years ago to help those deemed commercially uninsurable. Unfortunately, the program has been having enough money troubles of its owncollecting only about 45 percent of the cost of providing careand hasn't been able to accommodate the former customers of the liquidated companies.
After years of holding right around the 5,000 mark, enrollment surged by 10 percent in the first half of 2000. The new demand came partly from those who had been insured in the liquidated companies, but also because solvent companies have tightened underwriting guidelines and are turning down almost anyone who had ever been treated for hypertension or with asthma, explains Janet Kirby, director of underwriting for the program. In addition, those in the program are getting more expensive care. "When they become ill, they become quite ill," Kirby says. In 1999, 182 enrollees had claims of more than $50,000. Last year, the number topping that level was 238.
The program has stopped taking new members, and Gov. George Ryan is seeking a supplemental appropriation. Until it comes through, there's a waiting list, and about 15 percent of those on it were once insured by the out-of-business firms.
Daniel Moskowitz. Illinois trips over its own insurance regs.
Business and Health
2001;4:21.
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves First-Ever Cell Therapy Treatment for Rare Progressive Eye Disease
March 20th 2025Encelto is small, semi-permeable capsule implanted in the eye that contains allogeneic retinal pigment epithelium cells genetically engineered to produce specific therapeutic proteins. It will be available in June 2025.
Read More